ADAR1 Capital Management LLC Takes Position in Inspire Medical Systems, Inc. $INSP

Key Points

• ADAR1 Capital Management acquired 374,617 shares of Inspire Medical Systems in the second quarter, worth approximately $16.7 million and representing about 1.3% of the company. Institutional investors collectively own 94.91% of INSP.
• Inspire reported quarterly revenue of $200.58 million and adjusted earnings of $0.14 per share, beating analyst expectations, though revenue declined 7.6% year over year. The company issued fiscal 2026 EPS guidance of $1.05 to $1.45.
• INSP opened at $61.23, while analysts maintain a consensus “Hold” rating with an average price target of $66.19. Analyst views range from UBS’s $39 sell target to Stifel’s $75 target.

ADAR1 Capital Management LLC acquired a new stake in Inspire Medical Systems, Inc. (NYSE:INSP - Free Report) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 374,617 shares of the company's stock, valued at approximately $16,712,000. Inspire Medical Systems accounts for 0.8% of ADAR1 Capital Management LLC's investment portfolio, making the stock its 28th largest holding. ADAR1 Capital Management LLC owned approximately 1.30% of Inspire Medical Systems as of its most recent SEC filing.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Daiwa Securities Group Inc. grew its position in Inspire Medical Systems by 38.7% during the second quarter. Daiwa Securities Group Inc. now owns 466 shares of the company's stock worth $60,000 after buying an additional 130 shares during the period. State of Wyoming lifted its position in shares of Inspire Medical Systems by 31.5% during the 4th quarter. State of Wyoming now owns 731 shares of the company's stock valued at $67,000 after acquiring an additional 175 shares during the period. Smartleaf Asset Management LLC boosted its stake in shares of Inspire Medical Systems by 84.0% during the 4th quarter. Smartleaf Asset Management LLC now owns 449 shares of the company's stock worth $42,000 after acquiring an additional 205 shares in the last quarter. Apollon Wealth Management LLC boosted its stake in shares of Inspire Medical Systems by 5.6% during the 1st quarter. Apollon Wealth Management LLC now owns 3,997 shares of the company's stock worth $206,000 after acquiring an additional 212 shares in the last quarter. Finally, Blair William & Co. IL grew its holdings in shares of Inspire Medical Systems by 5.1% in the 3rd quarter. Blair William & Co. IL now owns 4,865 shares of the company's stock worth $361,000 after acquiring an additional 234 shares during the period. Hedge funds and other institutional investors own 94.91% of the company's stock.

Inspire Medical Systems Price Performance

NYSE:INSP opened at $61.23 on Wednesday. Inspire Medical Systems, Inc. has a 1-year low of $38.91 and a 1-year high of $147.03. The firm has a 50 day simple moving average of $51.95 and a 200-day simple moving average of $52.50. The firm has a market cap of $1.77 billion, a PE ratio of 13.25, a P/E/G ratio of 4.67 and a beta of 0.70.

Inspire Medical Systems (NYSE:INSP - Get Free Report) last issued its quarterly earnings results on Monday, August 3rd. The company reported $0.14 earnings per share for the quarter, beating the consensus estimate of ($0.24) by $0.38. Inspire Medical Systems had a return on equity of 8.64% and a net margin of 15.03%.The company had revenue of $200.58 million during the quarter, compared to the consensus estimate of $194.72 million. During the same period in the previous year, the firm posted $0.45 EPS. Inspire Medical Systems's revenue was down 7.6% on a year-over-year basis. Inspire Medical Systems has set its FY 2026 guidance at 1.050-1.450 EPS. As a group, sell-side analysts expect that Inspire Medical Systems, Inc. will post 1.24 earnings per share for the current fiscal year.

Insider Activity at Inspire Medical Systems

In other news, insider Jason P. Kelly sold 963 shares of Inspire Medical Systems stock in a transaction on Friday, August 7th. The stock was sold at an average price of $59.55, for a total value of $57,346.65. Following the completion of the sale, the insider owned 18,985 shares of the company's stock, valued at $1,130,556.75. The trade was a 4.83% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 2.20% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on INSP shares. Stifel Nicolaus set a $75.00 price objective on Inspire Medical Systems in a research note on Tuesday, August 4th. Zacks Research upgraded Inspire Medical Systems from a "hold" rating to a "strong-buy" rating in a research report on Monday, August 17th. Robert W. Baird upped their target price on Inspire Medical Systems from $54.00 to $59.00 and gave the company a "neutral" rating in a report on Tuesday, August 4th. UBS Group initiated coverage on Inspire Medical Systems in a research report on Tuesday, July 28th. They issued a "sell" rating and a $39.00 price target for the company. Finally, Summit Redstone set a $39.00 price target on Inspire Medical Systems in a research note on Friday, May 22nd. Two equities research analysts have rated the stock with a Strong Buy rating, three have given a Buy rating, eleven have assigned a Hold rating and three have issued a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus target price of $66.19.

Inspire Medical Systems Profile

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company's flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.